TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9118789

Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin and 500 mg metronidazole intravenously, twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no initial antibiotics), n = 13
Number of subjects: 13
Study: 8335858

Group type: EXPERIMENTAL
Intervention: Regular use of Beconase AQ nasal spray (400 micrograms daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: As required (prn) use of Beconase AQ nasal spray
Number of subjects: 60
Study: 3726286

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (250 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 10
Study: 29935863

Group type: COMPARATOR
Intervention: Rifaximin (R-group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metronidazole (M-group)
Number of subjects: 120
Study: 26912641

Group type: EXPERIMENTAL
Intervention: Anodal-transcranial direct current stimulation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham-transcranial direct current stimulation
Number of subjects: 26
Study: 25122693

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus 5-FU, leucovorin and oxaliplatin (Folfox-4) followed by bevacizumab-5-FU-RT before total mesorectal excision (TME)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bevacizumab-5-FU-RT before TME
Number of subjects: 91
Study: 22289150

Group type: EXPERIMENTAL
Intervention: JNJ-Q2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sparfloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 0
Study: 19070383

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5‐5mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: ARB (losartan 25‐50mg/day, candesartan 4‐8 mg/day, valsartan 40‐80 mg/day, telmisartan 20‐40 mg/day)
Number of subjects: 104
Study: 17454163

Group type: EXPERIMENTAL
Intervention: Phyto‐Female Complex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 14757258

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic Therapy
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Glucosamine/Chondroitin
Number of subjects: 706
Study: 12380633

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 283
Study: 10541948

Group type: EXPERIMENTAL
Intervention: Variant (TA)7/(TA)7 promoter in normal and G6PD-deficient newborns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects from the same population
Number of subjects: 0
Study: 7594320

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 16
Study: 2129071

Group type: EXPERIMENTAL
Intervention: High-dose glycyrrhizin (Stronger Neo-Minophagen C, SNMC) administered intravenously daily for the first 3 weeks, and every second day for the following 8 weeks. Dosage: 100-200 ml in 21 patients and 400-800 ml in the other 21.
Number of subjects: 42
Study: 7380749

Group type: EXPERIMENTAL
Intervention: Behavioral intervention and methylphenidate (0.25 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Behavioral intervention and methylphenidate (0.75 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose of methylphenidate after 13 weeks of behavioral intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose of methylphenidate after 13 weeks of behavioral intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: No medication after 13 weeks of behavioral intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 8
Study: 31410968

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Number of subjects: 15445

Group type: COMPARATOR
Intervention: Standard 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 15445

Group type: EXPERIMENTAL
Intervention: 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Number of subjects: 15445
Study: 30554789

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and resistance exercise
Number of subjects: 118
Study: 28364507

Group type: EXPERIMENTAL
Intervention: 1-hr nap opportunity at 14:00 following each sleep-restricted night
Number of subjects: 57

Group type: COMPARATOR
Intervention: No nap (stayed awake)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sleep restriction (5-hr time in bed for five nights and 3 nights)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 9-hr time in bed each night
Number of subjects: 57
Study: 26993316

Group type: EXPERIMENTAL
Intervention: Cold stimulus
Number of subjects: 7

Group type: COMPARATOR
Intervention: Room temperature (RT)
Number of subjects: 7
Study: 25081735

Group type: EXPERIMENTAL
Intervention: Isotretinoin with additional antihistamine (desloratadine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotretinoin only
Number of subjects: 40
Study: 22472454

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (beta‐carotene, selenium, vitamins C and E) in addition to methimazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methimazole only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (test and control)
Number of subjects: 0
Study: 19734185

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg/day
Number of subjects: 27
Study: 17308252

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fermentable fiber
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Standard enteral formula with Synbiotic 2000
Number of subjects: 113
Study: 15350314

Group type: EXPERIMENTAL
Intervention: Visual field progression detected with pointwise linear regression (PLR) analysis.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Older age at the initial intervention.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Larger IOP fluctuation.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Increasing number of glaucoma interventions.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Longer follow-up time.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: IOP fluctuation in eyes with and without a history of cataract extraction.
Number of subjects: 401
Study: 11453234

Group type: EXPERIMENTAL
Intervention: Bioactive glass implantation (test group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flap procedure only (control group)
Number of subjects: 38
Study: 9850904

Group type: EXPERIMENTAL
Intervention: Superior corneal incision (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Superior scleral incision (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Temporal corneal incision (Group 3)
Number of subjects: 90
Study: 8208173

Group type: EXPERIMENTAL
Intervention: Portfolio teaching with tutors (general practitioners or consultants) and longitudinal follow-up of three consenting cancer patients, including bimonthly tutorials.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard curriculum teaching only (control group).
Number of subjects: 3
Study: 2479083

Group type: EXPERIMENTAL
Intervention: Self-administration of pancreatic enzyme substitution (Pancrease)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular dosage of pancreatic enzyme substitution (Pancrease)
Number of subjects: 10
Study: 1096685

Group type: EXPERIMENTAL
Intervention: naphazoline hydrochloride 0.05%
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: antazoline phosphate 0.5%
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: combination of naphazoline hydrochloride and antazoline phosphate
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 31536941

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic clamp (plasma glucose: 3.1 ± 0.3 mmol/L)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normoglycaemic clamp (plasma glucose: 5.8 ± 0.3 mmol/L)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Comparison of cognitive discrepancy between hypoglycaemia and normoglycaemia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Factors associated with cognitive discrepancy
Number of subjects: 25
Study: 27779565

Group type: EXPERIMENTAL
Intervention: Combined exercise (EX) for 12 weeks, 3 times per week, intensity increased from 40% to 70% of heart rate reserve
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 20
Study: 26403986

Group type: EXPERIMENTAL
Intervention: Oral arsenic (Realgar‐Indigo naturalis formula, RIF) plus all‐trans retinoic acid (ATRA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) plus ATRA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral arsenic (RIF) during maintenance treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) during maintenance treatment
Number of subjects: 60
Study: 23999661

Group type: EXPERIMENTAL
Intervention: 1.1 g of n‐3 PUFA daily for six weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 g of olive oil daily for six weeks
Number of subjects: 50
Study: 22165459

Group type: EXPERIMENTAL
Intervention: 0.5% plain ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 60
Study: 18998188

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yogurt (1.6 g esterified phytosterols, equivalent to 1.0 g free phytosterol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Phytosterol-free placebo-controlled diet
Number of subjects: 15
Study: 16452747

Group type: EXPERIMENTAL
Intervention: Weekly dry dressing changes without pin-site care
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Daily pin-site care with a solution of one-half normal saline solution and one-half hydrogen peroxide
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated discs (Biopatch) with weekly changes
Number of subjects: 118
Study: 15233286

Group type: EXPERIMENTAL
Intervention: Spectral Analysis (SA) using 99mTc-HMPAO
Number of subjects: 17

Group type: COMPARATOR
Intervention: Graphical Analysis (GA) using 99mTc-HMPAO
Number of subjects: 17
Study: 11407040

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 26

Group type: COMPARATOR
Intervention: Blade plate
Number of subjects: 26
Study: 8990337

Group type: EXPERIMENTAL
Intervention: Intervention group (n=336)
Number of subjects: 874
Study: 8929232

Group type: EXPERIMENTAL
Intervention: Bunazosin retard (6 mg)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 343
Study: 2647578

Group type: EXPERIMENTAL
Intervention: arbaprostil 10 micrograms q.i.d.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 750190

Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF2a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-amniotic 15 Me PGF2a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extra-amniotic 15 Me PGF2a
Number of subjects: 0
Study: 30940489

Group type: EXPERIMENTAL
Intervention: High fat Atkins diet (4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fat Ornish diet (4 weeks)
Number of subjects: 0
Study: 28347792

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 27872106

Group type: EXPERIMENTAL
Intervention: Plasma glycine concentrations
Number of subjects: 2571

Group type: EXPERIMENTAL
Intervention: Plasma serine concentrations
Number of subjects: 2571

Group type: EXPERIMENTAL
Intervention: MTHFD1 rs2236225 polymorphism
Number of subjects: 2571

Group type: EXPERIMENTAL
Intervention: MTHFD1 rs1076991 polymorphism
Number of subjects: 2571
Study: 22893556

Group type: EXPERIMENTAL
Intervention: Customized fetal growth norms (SGAcust)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Population fetal growth norms (SGApop)
Number of subjects: 1092
Study: 21057883

Group type: EXPERIMENTAL
Intervention: More teaching-intensive hospitals
Number of subjects: 8282802

Group type: COMPARATOR
Intervention: Less teaching-intensive hospitals
Number of subjects: 8282802

Group type: EXPERIMENTAL
Intervention: Combined medical group
Number of subjects: 8282802

Group type: EXPERIMENTAL
Intervention: Combined surgical group
Number of subjects: 8282802

Group type: EXPERIMENTAL
Intervention: Combined outcomes of readmission and death
Number of subjects: 8282802
Study: 19448947

Group type: EXPERIMENTAL
Intervention: Stethoscopes used in pediatric units
Number of subjects: 0
Study: 17304143

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.0-2.5 mg/kg per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mesalazine (4 g/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 21
Study: 14973100

Group type: EXPERIMENTAL
Intervention: Unconditional incentive (30-min prepaid phone card provided concurrently with the survey)
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Conditional incentive (30-min prepaid phone card provided only upon receipt of completed survey)
Number of subjects: 1402
Study: 11211372

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 11
Study: 8878220

Group type: EXPERIMENTAL
Intervention: High dose vitamin A therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 8620046

Group type: EXPERIMENTAL
Intervention: Long Chain Triglycerides (LCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medium and Long Chain Triglycerides (MCT/LCT)
Number of subjects: 0
Study: 6366346

Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of indomethacin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 31842962

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 27317036

Group type: EXPERIMENTAL
Intervention: Laser visual guidance (LVG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional two-dimensional vision
Number of subjects: 32
Study: 26663250

Group type: EXPERIMENTAL
Intervention: Washing without water (using disposable skin cleaning and caring materials)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Traditional bathing methods
Number of subjects: 500
Study: 25074046

Group type: EXPERIMENTAL
Intervention: adalimumab for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: adalimumab for 24 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 26
Study: 22494677

Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after first exposure
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after second exposure
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after third exposure
Number of subjects: 46
Study: 19056078

Group type: EXPERIMENTAL
Intervention: ABO compatible recipients
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: ABO incompatible recipients
Number of subjects: 1002
Study: 17599420

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy targeting HbA(1c) level <6.0%
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Fibrate and statin therapy for lipid management
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure targeting <120 mm Hg
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Various levels of loss of visual acuity at 4 years versus baseline
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Cataract extraction
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Development or progression of diabetic macular edema
Number of subjects: 3537
Study: 15691617

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bendroflumetazide 2.5 mg for 4 weeks
Number of subjects: 24
Study: 11773924

Group type: EXPERIMENTAL
Intervention: Trial patients (n=264)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control subjects (n=335)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 599

Group type: COMPARATOR
Intervention: Trial patients vs Control subjects
Number of subjects: 599
Study: 9794277

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) - 12 weekly sessions of individual CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 8560527

Group type: COMPARATOR
Intervention: Dextrose 2 mg/kg/min infused over 60 min with heparin and Intralipid (group C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dextrose 2 mg/kg/min infused over 60 min alone (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dextrose 4 mg/kg/min alone (group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dextrose 4 mg/kg/min with heparin and Intralipid (group D)
Number of subjects: 32
Study: 2155688

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2.6 mg active drug per nostril, q.i.d.)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 6104973

Group type: EXPERIMENTAL
Intervention: Betaxolol (SL 75212)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31371081

Group type: EXPERIMENTAL
Intervention: Pentanethaquine hydrochloride (PHC)
Number of subjects: 90
Study: 27988180

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25308868

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride 25 mg
Number of subjects: 12
Study: 23570280

Group type: EXPERIMENTAL
Intervention: Infumorph
Number of subjects: 154

Group type: COMPARATOR
Intervention: Compounded morphine
Number of subjects: 154
Study: 21255424

Group type: EXPERIMENTAL
Intervention: Mammography 'implementation intentions' (MI2) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: General breast cancer prevention informational intervention (C)
Number of subjects: 0
Study: 19351732

Group type: EXPERIMENTAL
Intervention: Oral estradiol and progesterone for 7 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: P-insensitive HA girls
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tanner 1-2 NC
Number of subjects: 52
Study: 17722473

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with nadroparin s.c. only during bed immobilization
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with nadroparin s.c. for 10 additional days after bed immobilization
Number of subjects: 300

Group type: COMPARATOR
Intervention: Both groups (during thromboprophylaxis)
Number of subjects: 300
Study: 14748902

Group type: EXPERIMENTAL
Intervention: Echinacea (Echinilin)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 11522495

Group type: EXPERIMENTAL
Intervention: HDV-insulin (0.1 U/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular insulin (0.1 U/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HDV-insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 9
Study: 9597414

Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (1) and (2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of surgery (anastomosis or subclavian flap)
Number of subjects: 0
Study: 7928912

Group type: EXPERIMENTAL
Intervention: Ozone exposure (various concentrations) for 2 or 6.6 hours
Number of subjects: 374
Study: 3302342

Group type: EXPERIMENTAL
Intervention: Ampicillin suppository (4 x 125 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral form of ampicillin (4 x 125 mg)
Number of subjects: 105
Study: 31033625

Group type: EXPERIMENTAL
Intervention: Preoperative bilateral US-guided erector spinae plane (ESP) block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard (opioid-based) analgesia (Control group)
Number of subjects: 0
Study: 29581161

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 27549570

Group type: EXPERIMENTAL
Intervention: Community-based participatory nutrition promotion (CPNP) programme
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Government nutrition programmes only
Number of subjects: 1790
Study: 26144575

Group type: EXPERIMENTAL
Intervention: Automated FiO2 (A-FiO2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual FiO2 (M-FiO2)
Number of subjects: 80
Study: 22957521

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (insulin-dosing algorithm targeting blood glucose level of 80 to 110 mg/dL)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Standard care in the cardiac ICU
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 980

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 980
Study: 21151978

Group type: EXPERIMENTAL
Intervention: AQP5 polymorphisms (specifically three of the five SNPs tested) in continuous smokers
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Haplotype tests of AQP5 SNPs
Number of subjects: 429

Group type: COMPARATOR
Intervention: Wild-type AQP5 in HBE16 cells under shear stress and cigarette smoke extract (CSE 10%)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: N228K AQP5 plasmid in HBE16 cells under shear stress and CSE
Number of subjects: 429